Product Price Catalogue

• • Download Hyphen BioMed Product/Price Catalogue

---

Interactive Poster(s)

Blood Coagulation Poster

• • Activation, Regulation, Inhibition of Blood Coagulation Poster with Corresponding Products
    Author: HYPHEN BioMed, February 2010

---

HEMOCLOT

HEMOCLOT – Schemes

• • The Modern Approach for Clotting Assays
    Author: HYPHEN BioMed, September 2009

Direct Thrombin Inhibitors

• • • Dabigatran Calibrator and Control Plasmas for Drug Measurement in Plasma, When Required (Ref. A222801, A224701)
      Author: J. Amiral, M. Peyrafitte – HYPHEN BioMed & Stangier J. – Boehringer Ingelheim Pharma Gmbh & Co KG, GTH – February 2011

• • • Interference of Routine Coagulation Tests with the New Oral Anticoagulant Dabigatran – A Multicenter Study. (Ref. A222801, A224701)
      Author: Weigel G., Loacker L.J. , Griesmacher A. , Tomasits J, Halbmayer W.M., Quehenberger P., Aspöck G., Haushofer A., 2011

• • • New Assays for Measuring Direct Thrombin Inhibitors in Plasma (Ref. ACK002K, ACK002L, ASC030K, ASC035K)
      Author: M. Peyrafitte, A.M. Vissac, J. Amiral – HYPHEN BioMed, ISTH – July 2009

• • Direct Thrombin Inhibitors’ Activity Measurement in Plasma (ref. ASC030K, ASC035K, ACK002K, ACK002L, A220202)
    Author: M. Peyrafitte, A.M. Vissac, J. Amiral – HYPHEN BioMed, February 2009

Protein C / Protein S and AT III Pathways

• • Highly Stable and Robust Protein S Clotting Assay Validated for an Easier Laboratory Practice (Ref. ACK041K)
    Author: M. Peyrafitte, A.M. Vissac, J. Amiral – HYPHEN BioMed, GTH – February 2011

Factor V-Leiden

• • • Evaluation of a Novel Quantitative Assay for Factor V Leiden (Ref. ACK065K)
      Author: Hickey KP, Cooper PC, Kitchen S. – Sheffield Haemophilia and Thrombosis Centre, Royal Hallamshire Hospital, February 2010

• • Quantitative Measurement of Factor V Leiden in Heterozygous and Homozygous Patients for the R506Q Factor V Mutation (Ref. ACK065K, ACK071, ARK009A)
    Author: AM. Vissac, M. Peyrafitte, J. Amiral – HYPHEN BioMed, C. Leroy-Matheron – Lab Hémostase, GTH – February 2009

---

BIOPHEN

Factor VIII:C

• • Factors Affecting the Factor VIII:C Reactivity When Tested in Purified Systems With Chromogenic Assays (Ref. A221402)
    Author: Amiral J, Vissac AM – HYPHEN BioMed, July 2007

Anti-Xa Heparin Assays

• • Comparison of Two Anti-Xa Heparin Assays That Use a Single (Hybrid) Calibration Curve for Unfractionated and Low Molecular Weight Heparin (Ref. A221010)
    Author: McGlasson DL, Fritsma GA – Wilford Hall Medical Center, June 2007

Factor IX and X

• • New Standardized Chromogenic Assays for Automated Measurements of FIX or FIXa in Plasma and Therapeutic Concentrates (Ref. A221802, A221806, A221812)
    Author: M. Peyrafitte, A.M. Vissac, J. Amiral – HYPHEN BioMed, GTH – February 2009

Direct Xa Inhibitors

• • • BIOPHEN DiXaI – For the Quantitative Determination of Direct Factor Xa Inhibitors in Plasma
      Author: Kris Van Assche – Nodia, Bayer – Belgium, February 2012

• • • Specific and Rapid Measurement of Rivaroxaban in Plasma using a New, Dedicated, Chromogenic Assay
      Author: Samama M.M., Amiral J., Guinet C., Perzborn E., Depasse F. – Hotel Dieu University Hospital, HYPHEN BioMed, Biomnis Laboratories R&D, Research, Bayer HealthCare, GTH – February 2010

• • BIOPHEN DiXaI Powerpoint (Ref. A221030)
    Author: Jonas Kingo – Aniara, February 2010

---

ZYMUTEST

ZYMUTEST – Schemes

• • • Development of an Individual Anti-Factor VIII Inhibitors ELISA to Improve Hemophiliacs Therapeutic Follow Up (Ref. ARK039A)
      Author: Peyrafitte M., Vissac A.M., Amiral J. – HYPHEN BioMed, GTH – February 2011

• • • Fibrinolysis Mechanisms – Characteristics of Proteins Involved in Fibrinolysis
      Author: HYPHEN BioMed, April 2010

• • • Exploring Fibrinolysis with Today’s Technologies
      Author: HYPHEN BioMed, April 2010

• • Fibrinolysis and Thrombosis Enzyme Immuno Assays for the Exploration of Fibrinolysis in Human Plasma (Ref. ZYMUTEST line / Rat Immunochemicals / Rat Biochemicals)
    Author: Véronique Penissard – HYPHEN BioMed, April 2006

Von Wilebrand Factor

• • Evaluation of a New Collagen Binding Assay (Ref. ARK038A)
    Author: Kappert G, Rott H, Halimeh S, January 2012

Cross-Reactivities with Animal Proteins

• • Cross-Reactivities with Homologous Animal Proteins for the Various ZYMUTEST Kits
    Author: HYPHEN BioMed, August 2008

---

HIT Assays

• • • Diagnosis and Management of Vaccine-Related Thrombosis following AstraZeneca COVID-19 Vaccination: Guidance Statement from the GTH
      Authors: Johannes Oldenburg, Robert Klamroth, Florian Langer, Manuela Albisetti, Charis von Auer, Cihan Ay, Wolfgang Korte, Rüdiger E. Scharf, Bernd Pötzsch1 Andreas Greinacher

• • • Successful treatment of vaccine-induced prothrombotic immune thrombocytopenia (VIPIT)
      Authors: Johannes Thaler, Cihan Ay, Karoline V. Gleixner, Alexander W. Hauswirth, Filippo Cacioppo, Jürgen Grafeneder, Peter Quehenberger, Ingrid Pabinger, Paul Knöbl

• • • ZYMUTEST HIA (IgG or IgGAM)
      Author: Hyphen BioMed, October 2007

• • • ZYMUTEST HIA Algorithm (Ref. ARK040A)
      Author: Hans G. Zwerger – CoaChrom Diagnostica – March 2013

• • • Antibodies to Protamine Sulfateor to its Complexes with Heparin can be the Sole Ones Identified in Some Patients with Suspicion of HIT
      Author: Amiral J., Vissac A.M. – HYPHEN BioMed, GTH – February 2010

• • • Heterogenity of Heparin Induced Antibody Profiles in Patients Suspected of Heparin Induced Thrombocytopenia (HIT)
      Author: Vissac A.M., Amiral J. – HYPHEN BioMed, GTH – February 2010

• • • Can We Improve Clinical Specificity for HIT Immunoassays? (Ref. ARK040A, ARK040B, ARK040C, ARK040D, ARK040E, ARK041A, ARK041D)
      Author: A.M. Vissac, J. Amiral – HYPHEN BioMed, ISTH – July 2009

• • • Improved Clinical Specificity of Heparin Induced Thrombocytopenia Immunoassay (Ref. ARK040A, ARK040B, ARK040C, ARK040D, ARK040E)
      Author: AM. Vissac, M. Peyrafitte, J. Amiral – HYPHEN BioMed, GTH – February 2009

• • • Association of Protamine Sulfate Antibodies with “Pseudo-HIT” in Heparin Treated Patients (Ref. ARK040A, ARK040B, ARK040C, ARK040D, ARK040E)
      Author: J. Amiral, AM. Vissac – HYPHEN BioMed, GTH – February 2009

• • • New Approach for Detection Of Heparin Dependent Antibodies and Risk Assessment for Heparin Induced Thrombocytopenia – HIT Assays
      Author: Amiral J, Peyrafitte M, Catala M, Vissac AM – HYPHEN BioMed, July 2007

• • Incidence of the Various Heparin Dependent Antibody Isotypes in a Group of Patients With Heparin Induced Thrombocytopenia – HIT Assays
    Author: Vissac AM, Catala M, Amiral J, – HYPHEN BioMed, July 2007

---

Microparticles

• • • Microparticles Exposing Tissue Factor in Human Plasma (Ref. A521196)
      Author: Laroche M., Peyrafitte M., Vissac A.M. , Amiral J. – HYPHEN BioMed, GTH – February 2011

• • • The Multiple Faces of Tissue Factor Measured with Laboratory Assays (Ref. A521196, ARK035A, ARK042A)
      Author: Laroche M., Peyrafitte M., Vissac A.M. , Amiral J. – HYPHEN BioMed, GTH – February 2011

• • Microparticles Procoagulant Activity in Citrated Plasma (Ref. A521096)
    Author: AM. Vissac, M. Peyrafitte, J. Amiral – HYPHEN BioMed, July 2007

---

Technical Files

Heparin Kits

• • • BIOPHEN Heparin (LRT) Technical File (Ref. A221011)
      Author: HYPHEN BioMed, July 2010

• • • BIOPHEN Heparin Anti-Xa (2 stages) USP/EP Technical File (Ref. A221010-USP)
      Author: Véronique Penissard – HYPHEN BioMed, February 2010

• • • BIOPHEN Heparin Anti-IIa (2 Stages) – USP/EP Technical File (Ref. A221025-USP)
      Author: Véronique Penissard – HYPHEN BioMed, February 2010

• • BIOPHEN Heparin Technical File (Ref. A221003, A221006)
    Author: Jean Amiral – HYPHEN BioMed, May 2006

Rivaroxaban

• • Rivaroxaban Technical File (Ref. A222701, A224501)
    Author: Laetitia FRANK – HYPHEN BioMed, April 2012

Chromogenic Kits

• • • BIOPHEN Arixtra Technical File (Ref. A224001, A222501)
      Author: HYPHEN BioMed, July 2010

• • • BIOPHEN DiXaI (Direct Inhibitors) Technical File (Ref. A221030)
      Author: HYPHEN BioMed, October 2009

• • • BIOPHEN Antithrombin (AT) Technical File (Ref. A221102, A221105)
      Author: Véronique Penissard – HYPHEN BioMed, August 2009

• • • BIOPHEN Protein C Technical File (Ref. A221205)
      Author: Véronique Penissard – HYPHEN BioMed, August 2009

• • • BIOPHEN Factor VIII:C Technical File (Ref. A221402, A221406)
      Author: Véronique Penissard – HYPHEN BioMed, August 2009

• • BIOPHEN Factor X Technical File (Ref. A221705)
    Author: Jean Amiral – HYPHEN BioMed, April 2006

CEPHEN Kits

• • CEPHEN Technical File (Ref. ACK511K, ACK512K, ACK515K, ACK515L, ACK521K & ACK522K)
    Author: Véronique Penissard – HYPHEN BioMed, September 2009

HEMOCLOT Kits

• • • Protein S Technical File (Ref. ACK041K)
      Author: Laetitia Frank – HYPHEN BioMed, April 2012

• • • HEMOCLOT Thrombin Inhibitors Technical File (Ref. ACK002K, ACK002L)
      Author: HYPHEN BioMed, November 2010

• • • HEMOCLOT Protein C Technical File (Ref. ACK031K)
      Author: HYPHEN BioMed, July 2010

• • HEMOCLOT Thrombin Time (T.T.) Technical File (Ref. ACK011K, ACK011L)
    Author: Peyrafitte M. – HYPHEN BioMed, July 2006

LIAPHEN

• • • LIAPHEN AT Technical File (Ref. A120002)
      Author: HYPHEN BioMed, October 2011

• • LIAPHEN Fibrinogen Technical File – CE (Ref. A120102)
    Author: HYPHEN BioMed, March 2011

ZYMUTEST Kits

• • • ZYMUTEST Anti B2GPI IgG/IgM Technical File (Ref. ARK014A,ARK014B)
      Author: Véronique Penissard – HYPHEN BioMed, August 2009

• • • ZYMUTEST PAI-1 Antigen Technical File (Ref. ARK012A)
      Author: Jean Amiral – HYPHEN BioMed, May 2006

• • ZYMUTEST tPA Antigen Technical File (Ref. ARK011A)
    Author: Jean Amiral – HYPHEN BioMed, May 2006

---

Evaluation of Hyphen BioMed Chromogenic Substrates vs Chromogenix Substrates

• • • Comparison of Characteristics and Performances of Thrombin Chromogenic Substrates: Hyphen BioMed CS-01(38) vs Chromogenix S2238 (Ref. A229001, A229001-100, A229001-1, A229001-5)
      Author: M. Peyrafitte – HYPHEN BioMed, April 2009

• • • Comparison of Characteristics and Performances of FXa Chromogenic Substrate: Hyphen BioMed CS-11(22) vs Chromogenix S2222 (Ref. A229015, A229115, A229015-1, A229015-5)
      Author: M. Peyrafitte – HYPHEN BioMed, April 2009

• • • Comparison of Characteristics and Performance of FXa Chromogenic Substrate: Hyphen BioMed CS-11(32) vs Chromogenix S2732 (Ref. A229011, A229011-100, A229011-1, A229011-5)
      Author: M. Peyrafitte – HYPHEN BioMed, April 2009

• • • Comparison of Characteristics and Performances of FXa Chromogenic Substrate : Hyphen BioMed CS-11(65) vs Chromogenix S2765 (Ref. A229014, A229014-100, A229014-1, A229014-5)
      Author: M. Peyrafitte – HYPHEN BioMed, April 2009

• • • Comparison of Characteristics and Performances of Activated Protein C (aPC) Chromogenic Substrate: Hyphen BioMed CS-21(66) vs Chromogenix S2366 (Ref. A229021, A229021-100, A229021-1, A229021-5)
      Author: M. Peyrafitte – HYPHEN BioMed, April 2009

• • • Comparison of Characteristics and Performances of Plasmin/Plasminogen-SK Chromogenic Substrate: Hyphen BioMed CS-41(03) vs Chromogenix S2403 (Ref. A229041, A229041-100, A229041-1, A229041-5)
      Author: M. Peyrafitte – HYPHEN BioMed, April 2009

• • • Comparison of Characteristics and Performances of Urokinase (uPA) Chromogenic Substrate: Hyphen BioMed CS-61(44) (Ref. A229061, A229061-100, A229061-1, A229061-5)
      Author: M. Peyrafitte – HYPHEN BioMed, April 2009

• • Evaluation of chromogenic substrates: Hyphen BioMed vs Chromogenix – All Substrates
    Author: HYPHEN BioMed, February 2008

---

Industrial USP Heparin Reagents

• • Summary of Validation Criteria for Chromogenic Substrates (Especially CS-11(65) and CS-01(38)) for Human Antithrombin, Human Thrombin, Bovine FXa
    Author: HYPHEN BioMed, March 2010